tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

RGNX Stock Latest News

RGNX Earnings this Week: How Will it Perform?
Pre-EarningsRGNX Earnings this Week: How Will it Perform?
5h ago
RGNX
RBC sees Makary interview as potentially positive for biotech stocks
PremiumThe Fly
RBC sees Makary interview as potentially positive for biotech stocks
7d ago
DYN
RNA
Biotech stocks slide as Marks resignation seen being negative for sector
PremiumThe Fly
Biotech stocks slide as Marks resignation seen being negative for sector
28d ago
DYN
MGX
Marks resignation ‘not good’ for biotech sector, says RBC
PremiumThe Fly
Marks resignation ‘not good’ for biotech sector, says RBC
28d ago
DYN
RNA
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
1M ago
INO
ARCT
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating
PremiumRatingsRegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating
1M ago
RGNX
Optimistic Buy Rating for RegenXBio Driven by Promising RGX-202 Developments in DMD Treatment
Premium
Ratings
Optimistic Buy Rating for RegenXBio Driven by Promising RGX-202 Developments in DMD Treatment
1M ago
RGNX
Regenxbio reports data from Phase I/II portion of the Affinity Duchenne trial
Premium
The Fly
Regenxbio reports data from Phase I/II portion of the Affinity Duchenne trial
1M ago
RGNX
RegenXBio’s RGX-202: A Safe and Promising Gene Therapy with Best-in-Class Potential
PremiumRatings
RegenXBio’s RGX-202: A Safe and Promising Gene Therapy with Best-in-Class Potential
1M ago
RGNX
RegenXBio’s Promising Market Position and RGX-202’s Differentiated Safety Drive Buy Rating
PremiumRatings
RegenXBio’s Promising Market Position and RGX-202’s Differentiated Safety Drive Buy Rating
1M ago
RGNX
Sarepta update could boost enrollment in Regenxbio study, says Morgan Stanley
PremiumThe Fly
Sarepta update could boost enrollment in Regenxbio study, says Morgan Stanley
1M ago
RGNX
SRPT
Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink
PremiumThe Fly
Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink
1M ago
RGNX
SRPT
Analysts remain optimistic about Elevidys after Sarepta reports patient death
PremiumThe FlyAnalysts remain optimistic about Elevidys after Sarepta reports patient death
1M ago
RGNX
SLDB
Leerink says Sarepta stock reaction ‘overdone,’ remains positive on Elevidys
Premium
The Fly
Leerink says Sarepta stock reaction ‘overdone,’ remains positive on Elevidys
1M ago
RGNX
SLDB
Regenxbio price target lowered to $34 from $36 at H.C. Wainwright
Premium
The Fly
Regenxbio price target lowered to $34 from $36 at H.C. Wainwright
1M ago
RGNX
RegenXBio’s Strategic Advancements and Financial Stability Highlighted in Analyst Recommendation
PremiumRatings
RegenXBio’s Strategic Advancements and Financial Stability Highlighted in Analyst Recommendation
1M ago
RGNX
REGENXBIO Earnings Call Highlights Strategic Progress
PremiumCompany Announcements
REGENXBIO Earnings Call Highlights Strategic Progress
1M ago
RGNX
Regenxbio price target raised to $24 from $22 at Morgan Stanley
PremiumThe Fly
Regenxbio price target raised to $24 from $22 at Morgan Stanley
2M ago
RGNX
RegenXBio: Strong Buy Rating Backed by Clinical Progress and Solid Financial Position
PremiumRatings
RegenXBio: Strong Buy Rating Backed by Clinical Progress and Solid Financial Position
2M ago
RGNX
REGENXBIO Reports Progress in Gene Therapy Pipeline
PremiumCompany AnnouncementsREGENXBIO Reports Progress in Gene Therapy Pipeline
2M ago
RGNX
Regenxbio reports Q4 EPS ($1.01), consensus ($1.08)
Premium
The Fly
Regenxbio reports Q4 EPS ($1.01), consensus ($1.08)
2M ago
RGNX
RegenXBio: Positioned for Success in Gene Therapy Market with Strategic Partnerships and Strong Financials
Premium
Ratings
RegenXBio: Positioned for Success in Gene Therapy Market with Strategic Partnerships and Strong Financials
2M ago
RGNX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >